Stamford, CT -- (SBWIRE) -- 01/16/2014 -- OTC Stock Picks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: TriQuint Semiconductor (NASDAQ:TQNT), Raptor Pharmaceutical Corp. (NASDAQ:RPTP), Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL), Sarepta Therapeutics Inc (NASDAQ:SRPT)
TriQuint Semiconductor (NASDAQ:TQNT) opened the session at $8.59, trading in a range of $8.35 - $8.78. The stock showed a negative performance of -2.11% in the last trading session from its previous close of $8.55 and closed at $8.37. The stock traded on a volume of 3.06 million shares and the average volume of the stock remained 1.82 million shares. TriQuint Semiconductor, Inc. provides a portfolio of radio frequency (RF) solutions. The Company is a supplier of both active and passive technologies. It designs, develop and manufacture these power amplifier, switch and filters modules in-house. It focuses on three end markets in the electronic communications system industry: mobile devices, networks, and defense & aerospace.
Has TQNT Found The Bottom and Ready To Move Up? Find Out Here
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded 2.81 million shares in the last business day while the average volume of the stock remained 813,261 shares. The stock showed a negative movement of -2.07% to end at $15.17. The 52 week range of the stock remained $4.71 - $15.84. Raptor Pharmaceuticals Corp. (RPC), formerly TorreyPines Therapeutics, Inc., is an early development-stage Company. The Company’s product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. As of August 31, 2010, its pipeline includes three clinical development programs. It also has three other clinical-stage product candidates, for which it is seeking business development partners, and it has four preclinical product candidates it is developing, three of which are based upon its drug-targeting platforms.
Has RPTP Found The Bottom And Ready To Gain Momentum? Find Out Here
Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) reported 1.14 million shares were exchanged during the last trade, while the average volume is about 1.17 million shares. The stock dropped -2.04% and finished the day at $23.09. The beta of the stock is recorded at 0.58. Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences. It market two products: Testim testosterone gel and XIAFLEX (collagenase clostridium histolyticum). XIAFLEX is an injectable clostridial collagenase enzyme approved by the United States Food and Drug Administration (FDA) for the treatment of Dupuytren's contracture (Dupuytren's) in adult patients with a palpable cord.
Why Should Investors Buy AUXL After the Recent Fall? Just Go Here and Find Out
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares dropped -2.01 percent from its previous close of $20.39 to close at $19.98. Traded with volume of 1.80 million shares in the prior session and the average volume of the stock remained 1.77 million shares. Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. Its product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial.
Will SRPT Get Buyers Even After The Recent Rally? Find Out Here
About OTC Stock Picks
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.
Read full disclaimer at: http://otcstockpicks.net/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)